AUTHORS
Anupama Deepa Kumar, MD, Alexander Niyazov, PharmD., MPH, JD2, Sandeep Bilthare3, Rohitash Kumar Sharma4, Ajai Chari, MD5
AFFILIATIONS
1 UCSF, San Francisco, United States
2 Pfizer, Inc, New York, New York, United States
3 Putnam, New York, New York, United States
4 Putnam, New York, New York, United States
5 UCSF, San Francisco, United States
ABSTRACT
Introduction
Multiple myeloma accounts for about 10% of hematological malignancies. Over the last 15 years, many therapies have been approved for the treatment of multiple myeloma, including immunotherapies such as bispecific antibodies and CAR T-cell therapies. The impact of these novel therapies on patient outcomes in the real world is unknown. The main objective of our study was to evaluate trends and predictors of survival outcomes among patients diagnosed with multiple myeloma in the U.S.
Methods
Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) program (~48% of the U.S. population). Adults diagnosed with multiple myeloma (ICD-O-3 code for oncology: 9732/3) between 2010 and 2021 were included. Follow-up continued until death or December 2021. Kaplan-Meier methods estimated overall survival (OS) with median and 5-year survival rates reported. Log rank test was used to compare survival estimates. Cox proportional hazards models identified predictors of survival. 5-year relative survival rates were estimated for all patients and stratified by age group and race/ethnicity.
Results
A total of 59,067 multiple myeloma patients were included. Mean age in the overall cohort was 67 years (median age: 68 years); 60% were ≥65 years and 55% were male. Median OS was 60 months, with a 5-year survival rate of 49.6%. 5-year relative survival improved from 53% among patients diagnosed in the year 2010 (n=4,157) to 58% among patients diagnosed in the year 2015 (n=4,971) and 63% among patients diagnosed in the year 2021 (n=5,545).
Age, race, and sex were significant predictors of OS (p < 0.05). In patients between 18 and 60 years, median OS was 114 months with 5-year survival rates of 67%. In age groups 61 to 70 years, 70 to 80 years and >80 years, 5-year survival was 56%, 40 % and 18% respectively (p<0.001). 5-year relative survival trended higher in patients diagnosed in the year 2021 compared to those diagnosed in the year 2010 across all age groups (18 to 60 years: 65% to 75%; 61 to 70 years: 58% to 66%; 71 to 80 years: 44% to 56% and >80 years: 27% to 38%).
Patients who self-identified as Caucasian (n=41,972), Asian (n=3,968), and African American (n=12,093) had median OS of 57 months, 67 months, and 65 months, respectively (p <0.001). 5-year relative survival improved across all races from 2010 to 2021 (Caucasian 51% to 62%, Asian 53% to 64%, African American 57% to 64%).
Median OS was 62 months in females and 58 months in males. 5-year relative survival improved over time in both sexes from 2010 to 2021 (females 53% to 64%; males 53% to 62%).
Conclusion
Survival outcomes for patients with multiple myeloma across age groups and race/ethnicity subgroups have improved over the past decade, coinciding with the introduction of novel therapies in clinical practice. However, differences persist across race/ethnicity groups, and further work is needed to understand the drivers of these differences and address modifiable risk factors, including access to care. Moreover, the expected 5-year survival rate in the US general population for median age of 67 is 94% so continued development of novel therapies will be key to achieving further improvements in survival outcomes to achieve the goal of attaining expected outcomes of age matched healthy individuals. The impact of novel therapies on outcomes in multiple myeloma patients is eagerly anticipated.
DISCLOSURES
Anupama Deepa Kumar, MD: AstraZeneca - Honoraria; Legend Biotech - Honoraria; Johnson & Johnson - Honoraria; Johnson & Johnson - Research Funding; Bristol Myers Squibb - Research Funding; Poseida Therapeutics - Research Funding; AstraZeneca - Research Funding